Doylestown Health's Department of Medical Research is conducting three clinical trials for anemia related to chronic kidney disease.
About Chronic Kidney Disease and Anemia
Chronic kidney disease often leads to anemia which is a result of the kidney being diseased or injured. When a kidney is diseased or injured it will not produce enough erythropoietin, which is a hormone that triggers red blood cell production. People with anemia have too few red blood cells which leads to insufficient oxygen in the blood.
Often, anemia patients experience problems including fatigue, breathing issues and organ malfunctions, because red blood cells contain hemoglobin, an important protein that carries oxygen through the bloodstream.
Low iron levels can also lead to anemia, because red blood cells need sufficient iron in order to make hemoglobin.
Akebia and ASCEND-ND
"The Akebia and ASCEND-ND studies are for qualified individuals with chronic kidney disease who have low hemoglobin levels," says Phil Seger, RN, clinical research coordinator, Doylestown Hospital Medical Research, adding, "Though similar, each study has different requirements for patient participation."
The Akebia Therapeutics trial compares an investigational, oral medication against the standard, injectable medication. "In addition to evaluating the safety and effectiveness of the investigational drug, the potential of an oral medication would be more convenient and more comfortable than a needle," says Phil.
Similar to Akebia, the ASCEND-ND study is evaluating an investigational, oral medication against the standard injectable medication.
For people who suffer from chronic kidney disease with iron deficiency, Monofer is evaluating the safety and effectiveness of the investigational drug Monofer IV Iron against the standard of care, Venofer IV Iron. The standard medication requires five, 200 mg IV doses each given during a separate hospital visit. The investigational medication involves a one-time dose of 1,000 milligrams given intravenously over 20 minutes, according to Phil.
"Patients who qualify for the study can expect regular visits with a nurse, bloodwork and monitoring of symptoms. In these studies, we follow the patients for five years," says Phil, adding, "Participants are also contributing to science as part of a worldwide group that's helping to figure out if a medication is going to benefit others in the future."
A Leader in Clinical Research in Your Community
With more than 60 ongoing clinical trials in various specialties, Doylestown Health's commitment to clinical research brings the newest therapies to patients while helping to demonstrate the safety and effectiveness of treatments and devices. In addition, the research-based culture attracts physicians and nurses like Phil who want to be involved in the latest medical developments while continuing to provide hands-on patient care. "It is extremely interesting work," says Phil, adding, "I like the intricacies of the studies and the detail of it all, and there's nothing as rewarding as the follow-up because we get to know and care for the patients and their families over the long term."
Learn more about clinical trials
About Doylestown Health
Doylestown Health is a comprehensive healthcare system of inpatient, outpatient and wellness education services connected to meet the health needs of all members of the local and regional community. Doylestown Hospital, the flagship to Doylestown Health has 232 beds and a Medical Staff of more than 435 physicians in over 50 specialties. An independent nonprofit health system, Doylestown Health is dedicated to providing innovative, patient-centered care for all ages.
By posting on the Dialogue Online blog, I understand and agree that my comments will be reviewed and may be removed if they are libelous or otherwise illegal, or contain abusive, obscene, or otherwise inappropriate material. Please do not share personal health or financial information on the blog. I also understand that my comments will be available for view by the public and may be copied, stored, reproduced or disclosed by a third party for any use. For more information, please review the Doylestown Hospital's commenting guidelines.